Actos Damages Slashed But Takeda, Lilly Vow To Fight On
This article was originally published in PharmAsia News
A massive reduction in the amount of punitive damages awarded against Takeda and Lilly in an ongoing U.S. legal case concerning the bladder cancer risks of diabetes drug Actos is still not enough to satisfy the companies.
You may also be interested in...
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.